A Phase 3 interventional study of Pomalidomide and Bortezomib in Multiple Myeloma, sponsored by Celgene. Completed at 321 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-06.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies testing pomalidomide in Multiple Myeloma — 15 open to participants now, 39 under way, 9 of them phase 3. pomalidomide · Multiple Myeloma.
Among the 102 studies testing pomalidomide in Multiple Myeloma, this one is the 7th largest by enrollment, is one of 4 that started in 2013, is one of 17 in phase 3, and was the 19th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →15 of the 102 studies testing pomalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Shandong New Time Pharmaceutical Co., LTD · Sites in China
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
Celgene · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
pomalidomide: first FDA approval 2013 (POMALYST), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 75 · Phase 3 17 · Phase 4 2
First in 2007; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 559 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 102 interventional studies. Of the 48 that completed or were terminated, 24 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 102 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
149 studies in Multiple Myeloma by Bristol-Myers Squibb: 9 open now, 18 under way, 6 of them phase 3. Of 120 finished, 43 (36%) have results posted.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 11th largest by enrollment of the 108 interventional ones that give a count, is one of 8 that started in 2013, is one of 30 in phase 3, and was the 54th registered.
Bristol-Myers Squibb’s Multiple Myeloma studies by the year they started, since 2001.
10 of the studies testing pomalidomide in Multiple Myeloma that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05519085Phase 3CelgeneA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-01-10 |
| NCT05455320Phase 3Janssen Research & Development, LLCA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | 2027-07-30 |
| NCT02718833Massachusetts General HospitalA Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | 2026-12 |
| NCT04883242University of WashingtonIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
| NCT04508790City of Hope Medical CenterLeflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2027-02-14 |
Add all 10 to your calendar (.ics) → With an account.
Among the 102 studies testing pomalidomide in Multiple Myeloma, from their registry updates:
Among Bristol-Myers Squibb’s 149 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose dexamethasone to the combination of bortezomib and low dose dexamethasone in participants with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of pomalidomide, bortezomib and low dose dexamethasone is compared to the combination of bortezomib and low dose dexamethasone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 mg of Pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1.3 mg/m2 of Bortezomib administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\> 75 years old\] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2,8, 9 of 21 days for cycles 9 and onward until disease progression.
Drug: Pomalidomide · Drug: Bortezomib · Drug: Dexamethasone
1.3 mg/m2 of Bortezomib will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression along with Dexamethasone 20 mg/day \[≤ 75 years old\]or 10 mg/day \[\> 75 years old\] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
Drug: Bortezomib · Drug: Dexamethasone
Pomalidomide 4 mg will be taken orally on Days 1-14 of a 21-day cycle.
Also known as: Oral Pomalidomide, CC-4047
Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.
Also known as: Velcade
Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\>75 years old\] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
Progression Free Survival by Independent Response Adjudication Committee (IRAC)
Progression free survival (PFS) will be calculated as the time between the randomization and progressive disease (PD) or death. Progressive Disease is defined as an Increase of ≥ 25% from nadir in: * Serum M-component and/or (the absolute increase must be ≥ 0.5 g/dL)g * Urine M-component and/or (the absolute increase must be ≥ 200 mg/24 hours) * In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels, the absolute increase must be \> 100 mg/dL. * Bone marrow plasma cell percentage, the absolute % must be ≥ 10%h * Definite development of new bone lesions or soft tissue plasmacytomas increase in the size of existing bone lesions or soft tissue plasmacytomas. -Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder.
Time frame: From randomization to progressive disease or death during the IRAC assessment period, up to approximately 42 months
Overall Survival (OS)
Overall survival (OS) is calculated as the time from randomization to death from any cause.
Time frame: From randomization to date of death, up to approximately 65 months
Overall Response Rate by Independent Response Adjudication Committee (IRAC)
The ORR together with the relative proportions in each response category (ie, stringent CR \[sCR\], CR, very good PR \[VGPR\], PR, SD, and PD) by treatment using the IMWG criteria will be examined. Complete Response: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow SCR: CR+ Normal FLC ratio and Absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine Mprotein level \< 100 mg per 24 hours PR: ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours Progressive Disease: Please refer to Primary outcome measure for definition SD: Not meeting criteria for CR, VGPR, PR, or progressive disease
Time frame: From randomization to progressive disease or death during the IRAC assessment period, up to approximately 42 months
Duration of Response by Independent Response Adjudication Committee (IRAC)
Duration of myeloma response is defined as the duration from the time when the IMWG response criteria are first met for sCR or CR or VGPR or PR until the first date the response criteria are met for PD or until the subject died from any cause, whichever occurs first. Complete Response: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow SCR: CR+ Normal FLC ratio and Absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine Mprotein level \< 100 mg per 24 hours PR: ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours Progressive Disease: Please refer to Primary outcome measure for definition SD: Not meeting criteria for CR, VGPR, PR, or progressive disease
Time frame: From randomization to progressive disease or death during the IRAC assessment period, up to approximately 42 months
Number of Participants With Grade 3-4 Treatment Emergent Adverse Events (TEAE)
Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first dose date of the study treatment and within 28 days after the last dose date.
Time frame: From first dose to 28 days after the last dose (up to approximately 44 months
Number of Participants With Grade 5 Treatment Emergent Adverse Events (TEAE)
Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first dose date of the study treatment and within 28 days after the last dose date.
Time frame: From first dose to 28 days after the last dose (up to approximately 44 months
| Milestone | Treatment 1: POM+BTZ+LD-DEX | Treatment 2: BTZ+LD-DEX |
|---|---|---|
| Started | 281 | 278 |
| Completed | 278 | 270 |
| Not completed | 3 | 8 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Clinical progression | 0 | 1 |
| Withdrew: Progressive disease | 0 | 2 |
| Withdrew: Withdrew informed consent | 0 | 4 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Randomization error | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Milestone | Treatment 1: POM+BTZ+LD-DEX | Treatment 2: BTZ+LD-DEX |
|---|---|---|
| Started | 278 | 270 |
| Completed | 0 | 0 |
| Not completed | 278 | 270 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Progressive disease | 167 | 165 |
| Withdrew: Adverse event | 39 | 52 |
| Withdrew: Withdrawal of consent | 25 | 22 |
| Withdrew: Death | 20 | 9 |
| Withdrew: Other reasons | 27 | 19 |
| Withdrew: Pregnancy | 0 | 1 |
Progression free survival (PFS) will be calculated as the time between the randomization and progressive disease (PD) or death. Progressive Disease is defined as an Increase of ≥ 25% from nadir in: * Serum M-component and/or (the absolute increase must be ≥ 0.5 g/dL)g * Urine M-component and/or (the absolute increase must be ≥ 200 mg/24 hours) * In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels, the absolute increase must be \> 100 mg/dL. * Bone marrow plasma cell percentage, the absolute % must be ≥ 10%h * Definite development of new bone lesions or soft tissue plasmacytomas increase in the size of existing bone lesions or soft tissue plasmacytomas. -Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder.
| Months | Treatment 1: POM+BTZ+LD-DEX | Treatment 2: BTZ+LD-DEX |
|---|---|---|
| Progression Free Survival by Independent Response Adjudication Committee (IRAC) | 11.20 (9.66 to 13.73) | 7.10 (5.88 to 8.48) |
Overall survival (OS) is calculated as the time from randomization to death from any cause.
| Months | Treatment 1: POM+BTZ+LD-DEX | Treatment 2: BTZ+LD-DEX |
|---|---|---|
| Overall Survival (OS) | 35.58 (28.55 to 41.20) | 31.61 (26.05 to 37.16) |
The ORR together with the relative proportions in each response category (ie, stringent CR \[sCR\], CR, very good PR \[VGPR\], PR, SD, and PD) by treatment using the IMWG criteria will be examined. Complete Response: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow SCR: CR+ Normal FLC ratio and Absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine Mprotein level \< 100 mg per 24 hours PR: ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours Progressive Disease: Please refer to Primary outcome measure for definition SD: Not meeting criteria for CR, VGPR, PR, or progressive disease
| Participants | Treatment 1: POM+BTZ+LD-DEX | Treatment 2: BTZ+LD-DEX |
|---|---|---|
| Stringent complete response | 9 | 2 |
| Complete Reponse | 35 | 9 |
| Very Good Partial Response | 104 | 40 |
| Partial Response | 83 | 88 |
| Stable Disease | 32 | 106 |
| Progressive Disease | 11 | 16 |
| Not Evaluable | 7 | 17 |
Duration of myeloma response is defined as the duration from the time when the IMWG response criteria are first met for sCR or CR or VGPR or PR until the first date the response criteria are met for PD or until the subject died from any cause, whichever occurs first. Complete Response: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow SCR: CR+ Normal FLC ratio and Absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine Mprotein level \< 100 mg per 24 hours PR: ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours Progressive Disease: Please refer to Primary outcome measure for definition SD: Not meeting criteria for CR, VGPR, PR, or progressive disease
| Months | Treatment 1: POM+BTZ+LD-DEX | Treatment 2: BTZ+LD-DEX |
|---|---|---|
| Duration of Response by Independent Response Adjudication Committee (IRAC) | 13.70 (10.94 to 18.10) | 10.94 (8.11 to 14.78) |
Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first dose date of the study treatment and within 28 days after the last dose date.
| Participants | Treatment 1: POM+BTZ+LD-DEX | Treatment 2: BTZ+LD-DEX |
|---|---|---|
| Number of Participants With Grade 3-4 Treatment Emergent Adverse Events (TEAE) | 259 | 194 |
Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first dose date of the study treatment and within 28 days after the last dose date.
| Participants | Treatment 1: POM+BTZ+LD-DEX | Treatment 2: BTZ+LD-DEX |
|---|---|---|
| Number of Participants With Grade 5 Treatment Emergent Adverse Events (TEAE) | 29 | 12 |
Collected over AEs and SAEs: From first treatment to 28 days after last dose, up to approximately 44 months on average of 10 months. All-Cause mortality: from randomization to end of the study, approximately 65 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment 1: POM + BTZ + LD-DEX | 197/281 (70.1%) | 177/278 (63.7%) | 276/278 (99.3%) |
| Treatment 2: BTZ + LD-DEX | 193/278 (69.4%) | 119/270 (44.1%) | 260/270 (96.3%) |
| Event | Treatment 1: POM + BTZ + LD-DEX | Treatment 2: BTZ + LD-DEX |
|---|---|---|
| PneumoniaInfections and infestations | 34/278 | 17/270 |
| PyrexiaGeneral disorders | 12/278 | 5/270 |
| InfluenzaInfections and infestations | 10/278 | 4/270 |
| Lower respiratory tract infectionInfections and infestations | 10/278 | 5/270 |
| General physical health deteriorationGeneral disorders | 5/278 | 9/270 |
| Atrial fibrillationCardiac disorders | 9/278 | 2/270 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 9/278 | 1/270 |
| Acute kidney injuryRenal and urinary disorders | 8/278 | 6/270 |
| DiarrhoeaGastrointestinal disorders | 5/278 | 6/270 |
| Septic shockInfections and infestations | 6/278 | 0/270 |
| Event | Treatment 1: POM + BTZ + LD-DEX | Treatment 2: BTZ + LD-DEX |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 150/278 | 29/270 |
| Peripheral sensory neuropathyNervous system disorders | 134/278 | 103/270 |
| ThrombocytopeniaBlood and lymphatic system disorders | 110/278 | 105/270 |
| FatigueGeneral disorders | 107/278 | 72/270 |
| ConstipationGastrointestinal disorders | 106/278 | 65/270 |
| DiarrhoeaGastrointestinal disorders | 102/278 | 82/270 |
| Oedema peripheralGeneral disorders | 101/278 | 54/270 |
| AnaemiaBlood and lymphatic system disorders | 87/278 | 72/270 |
| PyrexiaGeneral disorders | 72/278 | 33/270 |
| Upper respiratory tract infectionInfections and infestations | 71/278 | 51/270 |
| Age, Continuous(Years) | Treatment 1: POM+BTZ+LD-DEX | Treatment 2: BTZ+LD-DEX | Total |
|---|---|---|---|
| Mean | 65.9 ± 10.13 | 66.1 ± 10.16 | 66.0 ± 10.14 |
| Sex: Female, Male(Participants) | Treatment 1: POM+BTZ+LD-DEX | Treatment 2: BTZ+LD-DEX | Total |
|---|---|---|---|
| Female | 126 | 131 | 257 |
| Male | 155 | 147 | 302 |
| Ethnicity (NIH/OMB)(Participants) | Treatment 1: POM+BTZ+LD-DEX | Treatment 2: BTZ+LD-DEX | Total |
|---|---|---|---|
| Hispanic or Latino | 17 | 14 | 31 |
| Not Hispanic or Latino | 244 | 241 | 485 |
| Unknown or Not Reported | 20 | 23 | 43 |
| Race (NIH/OMB)(Participants) | Treatment 1: POM+BTZ+LD-DEX | Treatment 2: BTZ+LD-DEX | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 14 | 8 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 13 | 21 |
| White | 237 | 234 | 471 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 22 | 23 | 45 |
Showing the first 100 of 321 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2013 to primary completion in May 2022, 112 months.
Results were first posted in Jun 2023, 1 year after primary completion.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 112 months is above that.
Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pomalidomide